Degludec insulin
ApprovedSmall molecule
Sunshine Lake Pharma Co., Ltd.Degludec insulin is one of 37 small molecule programs targeting Diabetes Mellitus. It is currently in Approved.
1
Indications
3
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
286 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1LY2605541
Eli LillyPhase 3
Volinanserin
SanofiPhase 3
Degludec insulin
Sunshine Lake Pharma Co., Ltd.Approved
Trulicity
Eli LillyPreclinical
Byetta
AstraZenecaPreclinical
Galvus
NovartisPreclinical
NOVOLIN R
Novo NordiskPreclinical
Edarbi
TakedaPreclinical
Paxil CR
GSKPreclinical
Simponi
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetes Mellitus1 trial
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus
Enrolling by invitation·—·Phase 4·NCT06925334·170 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Degludec insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details